Medical Journal News

Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo controlled, flexible-dose phase 3 trial. Lancet 2024; 403: 160–70—In table 3 of this Article, the fifth-row header should read “TEAE occurring in ≥5% of participants in the KarXT group.” This correction has been made to the online version as of May 30, 2024.

Beck J, Fung C, Strbian D, et al. Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial. Lancet 2024; 403: 2395–404—In this Article, in the Research in context panel, the first sentence of the Implications of all the available evidence section should read “SWITCH provides some evidence that decompressive craniectomy plus best medical treatment might be superior to best medical treatment alone.” This correction has been made to the online version as of May 30, 2024, and the printed version is correct.

A 32-year-old man presented to our hospital with a 3-week history of fever, cough, and general fatigue; he also reported a 1-month history of night sweats. The patient had no significant medical history; he had been previously fit and well and was prescribed no medications.